Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer

Cancer Research

Volumn 63, Issue 2, 2003, Pages 513-521

  Mueller, Thomas ^a   Voigt, Wieland ^a   Simon, Heike ^a   Fruehauf, Angelika ^a   Bulankin, Andrej ^a   Grothey, Axel ^a   Schmoll, Hans Joachim ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 2; CASPASE 3; CASPASE 7; CASPASE 8; CASPASE 9; CISPLATIN; DNA; DNA NUCLEOTIDYLEXOTRANSFERASE; FAS ANTIGEN; FAS LIGAND; PROTEIN BCL 2; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DETERMINATION; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GERM CELL TUMOR; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MOLECULAR MECHANICS; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TESTIS CANCER;

ADULT; ANTIGENS, CD95; APOPTOSIS; CASPASE 8; CASPASE 9; CASPASES; CISPLATIN; DNA ADDUCTS; DNA DAMAGE; DNA, NEOPLASM; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; HUMANS; MALE; PROTO-ONCOGENE PROTEINS C-BCL-2; TESTICULAR NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0037439820     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Bosl, G. J., and Motzer, R. J. Testicular gerrn-cell cancer. N. Engl. J. Med., 337: 242-253, 1997.
2. Ozols, R. F., and Williams, S. D. Testicular cancer. Curr. Prob. Cancer. 13: 285-335, 1989.
3. Eastman, A. Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells, 2: 275-280, 1990.
4. Kerr, J. F., Winterford, C. M., and Harmon, B. V. Apoptosis. Its significance in cancer and cancer therapy. Cancer (Phila.), 73: 2013-2026, 1994.
5. Fisher, D. E. Apoptosis in cancer therapy: crossing the threshold. Cell, 78: 539-542, 1994.
6. Dive, C., and Hickman, J. A. Drug-target interactions: only the first step in the commitment to a programmed cell death? Br. J. Cancer, 64: 192-196, 1991.
7. Huddart, R. A., Titley, J., Robertson, D., Williams, G. T., Horwich, A., and Cooper, C. S. Programmed cell death in response to chemotherapeutic agents in human germ cell turnout lines. Eur. J. Cancer, 5: 739-746, 1995.
8. Alnemri, E. S., Livingston, D. J., Nicholson, D. W., Salvesen, G., Thornberry, N, A., Wong, W. W., and Yuan, J. Human ICE/CED-3 protease nomenclature. Cell, 87: 171, 1996.
9. Cryns, V., and Yuan, J. Proteases to die for. Genes Dev., 12: 1551-1570, 1998.
10. Thornberry, N. A., and Lazebnik, Y. Caspases: enemies within. Science (Wash. DC), 281: 1312-1316, 1998.
11. Sun, X. M., MacFarlane, M., Zhuang, J., Wolf, B. B., Green, D. R., and Cohen, G. M. Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis. J. Biol. Chem., 274: 5053-5060, 1999.
12. Budihardjo, I., Oliver, H., Lutter, M., Luo, X., and Wang, X. Biochemical pathways of caspase activation during apoptosis. Annu. Rev. Cell Dev. Biol., 15: 269-290, 1999.
13. Boldin, M. P., Goncharov, T. M., Goltsev, Y. V., and Wallach, D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell, 85: 803-815, 1996.
14. Scaffidi, C., Fulda, S., Srinivasan, A., Friesen, C., Li, F., Tomaselli, K. J., Debatin, K. M., Krammer, P. H., and Peter, M. E. Two CD95 (APO-1/Fas) signaling pathways. EMBO J., 17: 1675-1687, 1998.
15. Zou, H., Li, Y., Liu, X., and Wang, X. An APAF-1, cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J. Biol. Chem., 274: 11549-11556, 1999.
16. Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S. M., Ahmad, M., Alnemri, E. S., and Wang, X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell, 91: 479-489, 1997.
17. Friesen, C., Fulda, S., and Debatin, K. M. Cytotoxic drugs and the CD95 pathway. Leukemia (Baltimore), 13: 1854-1858, 1999.
18. Ferreira, C. G., Span, S. W., Peters, G. J., Kruyt, F. A., and Giaccone, G. Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small cell lung cancer cell line NCI-H460. Cancer Res., 60: 7133-7141, 2000.
19. Adams, J. M., and Cory, S. The Bcl-2 protein family: arbiters of cell survival. Science (Wash. DC), 281: 1322-1326, 1998.
20. Green, D. R., and Reed, J. C. Mitochondria and apoptosis. Science (Wash. DC), 281: 1309-1312, 1998.
21. Harris, C. C. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J. Natl. Cancer Inst. (Bethesda), 88: 1442-1455, 1996.
22. Chresta, C. M., Masters, J. R., and Hickman, J. A. Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. Cancer Res., 56: 1834-1841, 1996.
23. Wang, N., Trend, B., Bronson, D. L., and Fraley, E. E. Nonrandom abnormalities in chromosome 1 in human testicular cancers. Cancer Res., 40: 796-802, 1980.
24. Vogelzang, N. J., Bronson, D., Savino, D., Vessella, R. L., and Fraley, E. F. A human embryonal-yolk sac carcinoma model system in athymic mice. Cancer (Phila.), 55: 2584-2593, 1985.
25. Casper, J., Schmoll, H. J., Schnaidt, U., and Fonatsch, C. Cell lines of human germinal cancer. Int. J. Androl., 10: 105-113, 1987.
26. Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J. Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., and Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. (Bethesda), 82: 1107-1112, 1990.
27. Zhang, C., Ao, Z., Seth, A., and Schlossman, S. F. A mitochondrial membrane protein defined by a novel monoclonal antibody is preferentially detected in apoptotic cells. J. Immunol., 157: 3980-3987, 1996.
28. Tilby, M. J., Styles, J. M., and Dean, C. J. Immunological detection of DNA damage caused by melphalan using monoclonal antibodies. Cancer Res., 47: 1542-1546, 1987.
29. Tilby, M. J., Johnson, C., Knox, R. J., Cordell, J., Roberts, J. J., and Dean, C. J. Sensitive detection of DNA modifications induced by cisplatin and carboplatin in vitro and in vivo using a monoclonal antibody. Cancer Res., 51: 123-129, 1991.
30. Yamada, K., Ichikawa, F., Ishiyama-Shigemoto, S., Yuan, X., and Nonaka, K. Essential role of caspase-3 in apoptosis of mouse β-cells transfected with human Fas. Diabetes, 48: 478-483, 1999.
31. Bokemeyer, C., Kohrmann, O., Tischler, J., Weissbach, L., Rath, U., Haupt, A., Schoffski, P., Harstrick, A., and Schmoll, H. J. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors. Ann. Oncol., 7: 1015-1021, 1996.
32. Rie, C., Hammer, C., Voigt, W., Müller, T., Müller, L. P., Grothey, A., and Schmoll, H. J. Cytotoxicty of oxaliplatin (LOHP) versus cisplatin (CDDP) in xenotransplanted non-seminomatous germ cell cancer (NSGCC) cell lines. Proc. Am. Soc. Clin. Oncol., 19: 361a, 2000.
33. Thornberry, N. A., Rano, T. A., Peterson, E. P., Rasper, D. M., Timkey, T., Garcia-Calvo, M., Houtzager, V. M., Nordstrom, P. A., Roy, S., Vaillancourt, J. P., Chapman, K. T., and Nicholson, D. W. A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. J. Biol. Chem., 272: 17907-17911, 1997.
34. Talanian, R. V., Quinlan, C., Trautz, S., Hackett, M. C., Mankovich, J. A., Banach, D., Ghayur, T., Brady, K. D., and Wong, W. W. Substrate specificities of caspase family proteases. J. Biol. Chem., 272: 9677-9682, 1997.
35. Soini, Y., and Paakko, P. Extent of apoptosis in relation to p53 and bcl-2 expression in germ cell tumors. Hum. Pathol., 27: 1221-1226, 1996.
36. Heidenreich, A., Schenkman, N. S., Sesterhenn, I. A., Mostofi, K. F., Moul, J. W., Srivastava, S., and Engelmann, U. H. Immunohistochemical and mutational analysis of the p53 tumour suppressor gene and the bcl-2 oncogene in primary testicular germ cell tumours. Apmis, 106: 90-99; discussion 99-100, 1998.
37. Kersemaekers, A. M. F., van Weeren, P. C., Oosterhuis, J. W., and Looijenga, L. H. J. Involvement of the Fas/FasL pathway in the pathogenesis of germ cell tumours of the adult testis. J. Pathol., 196: 423-429, 2002.
38. Burger, H., Nooter, K., Boersma, A. W., Kortland, C. J., and Stoter, G. Lack of correlation between cisplatin-induced apoptosis, p53 status and expression of Bcl-2 family proteins in testicular germ cell tumour cell lines. Int. J. Cancer, 73: 592-599, 1997.
39. Burger, H., Nooter, K., Boersma, A. W., van Wingerden, K. E., Looijenga, L. H., Jochemsen, A. G., and Stoter, G. Distinct p53-independent apoptotic cell death signalling pathways in testicular germ cell tumour cell lines. Int. J. Cancer, 81: 620-628, 1999.
40. Liu, J. R., Opipari, A. W., Tan, L., Jiang, Y., Zhang, Y., Tang, H., and Nunez, G. Dysfunctional apoptosome activation in ovarian cancer: implications for chemoresistance. Cancer Res., 62: 924-931, 2002.
41. Wu, G. S., and Ding, Z. Caspase 9 is required for p53-dependent apoptosis and chemosensitivity in a human ovarian cancer cell line. Oncogene, 21: 1-8, 2002.
42. Schwartz, P. S., and Waxman, D. J. Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells. Mol. Pharmacol., 60: 1268-1279, 2001.
43. Kuwahara, D., Tsutsumi, K., Kobayashi, T., Hasunuma, T., and Nishioka, K. Caspase-9 regulates cisplatin-induced apoptosis in human head and neck squamous cell carcinoma cells. Cancer Lett., 148: 65-71, 2000.
44. Deveraux, Q. L., Roy, N., Stennicke, H. R., Van Arsdale, T., Zhou, Q., Srinivasula, S. M., Alnemri, E. S., Salvesen, G. S., and Reed, J. C. IAPs block apoptotic events induced by caspase-S and cytochrome c by direct inhibition of distinct caspases. EMBO J., 17: 2215-2223, 1998.
45. Dunn, T. A., Schmoll, H. J., Rie, C., Hartmann, K., and Casper, J. Production and pre-clinical significance of haematopoietic peptide growth factors (HPGF) in human non-seminomatous germ cell tumour cell lines. J. Cancer Res. Clin. Oncol., 124: 435-443, 1998.
46. Toner, G. C., Geller, N. L., Lin, S. Y., and Bosl, G. J. Extragonadal and poor risk nonseminomatous germ cell tumors. Survival and prognostic features. Cancer (Phila.), 67: 2049-2057, 1991.
47. Saxman, S., Nichols, C. R., Williams, S. D., Loehrer, P. J., and Einhorn, L. H. Mediastinal yolk sac tumor. The Indiana University experience, 1976 to 1988. J. Thorac. Cardiovasc. Surg., 102: 913-916, 1991.
48. Rick, O., Bokemeyer, C., Beyer, J., Hartmann, J. T., Schwella, N., Kingreen, D., Neureither, S., Metzner, B., Casper, J., Wandt, H., Hartmann, F., Schmoll, H. J., Derigs, G., Gerl, A., Berdel, W. E., Kanz, L., and Siegert, W. Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer. J. Clin. Oncol., 19: 81-88, 2001.
49. Bokemeyer, C., Kollmannsberger, C., Meisner, C., Harstrick, A., Beyer, J., Metzner, B., Hartmann, J. T., Schmoll, H. J., Einhorn, L., Kanz, L., and Nichols, C. First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: a multivariate and matched-pair analysis. J. Clin. Oncol., 17: 3450-3456, 1999.
50. Ozols, R. F. Poor prognosis germ cell tumors of the testes: improved results with high dose regimens. Prog. Clin. Biol. Res., 269: 419-427, 1988.